Progress in Clinical, Pharmacological, Chemical and Structural Biological Studies of Huperzine A: A Drug of Traditional Chinese Medicine Origin for the Treatment of Alzheimers Disease

HupA is a potent, reversible AChEI, which crosses the blood-brain barrier smoothly, and shows high specificity for AChE with a prolonged biological half-life. It has been approved as the drug for the treatment of AD in China, and marketed in USA as a dietary supplement. HupA has been the subject of...

Full description

Saved in:
Bibliographic Details
Published inCurrent medicinal chemistry Vol. 10; no. 21; pp. 2231 - 2252
Main Authors JIANG, Hualiang, LUO, Xiaomin, BAI, Donglu
Format Journal Article
LanguageEnglish
Published Oak Park, IL Bentham Science Publishers Ltd 01.11.2003
Bentham Science Publishers
Bentham Science
Subjects
Online AccessGet full text
ISSN0929-8673
1875-533X
DOI10.2174/0929867033456747

Cover

More Information
Summary:HupA is a potent, reversible AChEI, which crosses the blood-brain barrier smoothly, and shows high specificity for AChE with a prolonged biological half-life. It has been approved as the drug for the treatment of AD in China, and marketed in USA as a dietary supplement. HupA has been the subject of investigations by an ever-increasing number of researchers since 1980s. In the last four years, HupA has been further studied in many aspects such as the chemical synthesis, structural modification, structureactivity relationship, various biological effects, and mechanisms of action. A number of papers dealing with the computational modeling and X-ray crystallographic studies of HupA-AChE complex have also been published. This review represents a comprehensive documentation of the progress in the studies on HupA during the period of 1999-2002.
Bibliography:istex:A9F3A594ACC265D375E275E569A492BBFDCC4D82
ark:/67375/R65-4H130VTZ-X
ArticleID:CMC-10-21-2231
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ISSN:0929-8673
1875-533X
DOI:10.2174/0929867033456747